Bristol Myers Squibb Co (BMY): Anne Nielsen , Chief Compliance & Ethics Off of Bristol Myers Squibb Co sold 28,451 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 4, 2016 to the Securities and Exchange Commission. The shares were sold at $71.88 per share for a total value of $2,045,171.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, Lamberto Andreotti (director) sold 234,720 shares at $71.88 per share price.On May 4, 2016, Louis S Schmukler (Pres., Global Mfg. & Supply) sold 22,218 shares at $71.95 per share price.Also, On Mar 10, 2016, Lewis B Campbell (director) sold 2,500 shares at $66.00 per share price.On Mar 7, 2016, Joseph C Caldarella (SVP & Controller) sold 12,962 shares at $64.64 per share price.
Shares of Bristol-Myers Squibb Co (BMY) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.35 points or -0.49% at $70.78 with 68,35,183 shares getting traded. Post opening the session at $70.42, the shares hit an intraday low of $70.135 and an intraday high of $70.95 and the price vacillated in this range throughout the day. The company has a market cap of $118,154 M and the number of outstanding shares has been calculated to be 1,66,93,07,300 shares. The 52-week high of Bristol-Myers Squibb Co is $73.06 and the 52-week low is $51.82.
Company has been under the radar of several Street Analysts.Bristol-Myers Squibb Co is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $73 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 75 from a previous price target of $70 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Initiated by Societe Generale to Sell and the brokerage firm has set the Price Target at $48. The Rating was issued on Apr 6, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.